Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06920043 · ClinicalTrials.gov registry record · Phase 2
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
A Phase 2 study of Metabolic Dysfunction-associated Steatohepatitis, sponsored by Boston Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 20
- Study locations
NCT06920043: Recruiting Phase 2 study of Metabolic Dysfunction-associated Steatohepatitis, sponsored by Boston Pharmaceuticals.
NCT06920043 is a Phase 2 study of Metabolic Dysfunction-associated Steatohepatitis that is actively recruiting participants, run by Boston Pharmaceuticals. The registered enrollment target is 42 participants, below the 413-participant average among 5 other Metabolic Dysfunction-associated Steatohepatitis trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06920043, a Phase 2 study of Metabolic Dysfunction-associated Steatohepatitis, is actively recruiting participants, sponsored by Boston Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.
Primary Outcome
To assess the effects of efimosfermin on safety and tolerability.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Efimosfermin
Study Locations (20)
California
- Fresno Clinical Research Center - Fresno
- OM Research LLC - Lancaster
- Knowledge Research Center - Orange
- California Liver Research Institute - Pasadena
- Inland Empire Liver Foundation - Rialto
- Santa Maria Gastroenterology Center - Santa Maria
Arizona
- Arizona Liver Health - Chandler - Chandler
- Arizona Liver Health - Peoria - Peoria
- The Institute for Liver Health II LLC dba Arizona Liver Health - Tucson - Tucson
Florida
- ClinCloud Research - Maitland - Maitland
- ClinCloud Research - Viera - Melbourne
- Advanced Clinical Research of Miami - Miami
Georgia
- Centricity Research - Columbus - Columbus
- Gastrointestinal Specialists of Georgia PC - Marietta
North Carolina
- Coastal Research Institute, LLC - Fayetteville
- M3 Wake Research, Inc - Raleigh
Maryland
- Mercy Medical Center - Baltimore, Maryland - Baltimore
Mississippi
- Gastrointestinal Associates and Endoscopy Center, PA - Flowood - Flowood
Missouri
- Kansas City Research Institute - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2025-04-09 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
What NCT06920043 shows while recruiting
NCT06920043 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 413-participant average among 5 other Metabolic Dysfunction-associated Steatohepatitis trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Metabolic Dysfunction-associated Steatohepatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06920043 names 20 study sites across 9 states, led by California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT06920043 about?
NCT06920043 is a clinical study titled "A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH". The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.
What is the current status of trial NCT06920043?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2025-04-09. Estimated completion is 2027-12.
What conditions does trial NCT06920043 study?
This clinical trial studies the following conditions: Metabolic Dysfunction-associated Steatohepatitis.
What interventions are being tested in trial NCT06920043?
The interventions under investigation include: Placebo (DRUG), Efimosfermin (DRUG).
Who is sponsoring clinical trial NCT06920043?
This trial is sponsored by Boston Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06920043 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metabolic Dysfunction-associated Steatohepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
RECRUITING · Phase 2
-
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
ACTIVE NOT RECRUITING · Phase 2
-
ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)
COMPLETED · Phase 2
-
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
RECRUITING · NA
-
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI